Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD),
an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial …

Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in
clinical trials, may be the single outcome reflective of patient priorities when living with a …

Objective To develop response criteria for adult dermatomyositis (DM) and polymyositis
(PM). Methods Expert surveys, logistic regression, and conjoint analysis were used to …

Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical
practice. Methods We performed a prospective study including patients with SSc from the …

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and …

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack
of consensus on appropriate outcome measures for reliably assessing treatment response …

Background Interstitial lung disease (ILD) is a frequent manifestation of connective tissue
disease (CTD), especially systemic sclerosis (SSc), polymyositis-dermatomyositis, and …

The lung is one of the most common extra-muscular targets in idiopathic inflammatory
myopathies (IIM) and interstitial lung disease (ILD) is a prevalent and often devastating …